Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alon...
Saved in:
Main Authors: | Yue Qiu, Yaqin Shi, Zhujun Chao, Xinyu Zhu, Yan Chen, Linlin Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359241311379 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01) -
Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01) -
A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
by: Chenfei Zhou, et al.
Published: (2025-01-01) -
Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01) -
Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
by: Matteo Perra, et al.
Published: (2025-01-01)